Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the pharmacokinetics, safety, and tolerability of a new long-acting cabotegravir formulation given every four months for HIV infectio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Cabotegravir long-acting (cabotegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 2 | Status: ACTIVE_NOT_RECRUITING